Caroline Daly1, Eve Griffin2, Darren M Ashcroft3,4, Roger T Webb5, Ivan J Perry2,6, Ella Arensman2,6. 1. National Suicide Research Foundation, University College Cork, Room 4.28, Fourth Floor, Western Gateway Building, Western Road, Cork, Ireland. carolinedaly@ucc.ie. 2. National Suicide Research Foundation, University College Cork, Room 4.28, Fourth Floor, Western Gateway Building, Western Road, Cork, Ireland. 3. Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK. 4. NIHR Greater Manchester Patient Safety Translational Research Centre, University of Manchester, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK. 5. Centre for Mental Health and Safety, Division of Psychology and Mental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Sciences Centre (MAHSC), Manchester, UK. 6. School of Public Health, University College Cork, Cork, Ireland.
Abstract
INTRODUCTION: Intentional drug overdose (IDO) is a significant public health problem. Concerns about the misuse of gabapentinoids, i.e. pregabalin and gabapentin, including their consumption in IDO have grown in recent years. This paper examines the trends in the prevalence of gabapentinoids taken in IDO, the profile of individuals taking them, and associated overdose characteristics. METHODS: Presentations to emergency departments involving IDO, recorded by the National Self-Harm Registry Ireland between 1 January 2007 and 31 December 2015 were examined. Data items included patient demographics, drug names, total tablet quantity consumed and alcohol involvement. RESULTS: Gabapentinoids were involved in 2115 (2.9%) of the 72,391 IDOs recorded. Presentations involving a gabapentinoid increased proportionally from 0.5% in 2007 to 5.5% in 2015. The majority of IDOs involving a gabapentinoid were made by females (59.9%), with over one-third (37.2%) involving alcohol. Compared with IDOs involving other drugs, presentations with a gabapentinoid were made by persons who were older (median 37 vs. 32 years) and involved a significantly greater median quantity of tablets (30 vs. 21, p ≤ 0.001), with over one-quarter (27.4%) of these involving the ingestion of 50 tablets or more. Admission to hospital was significantly more common following IDOs with a gabapentinoid compared with those without (49.4% vs. 41.4%, p ≤ 0.001). CONCLUSIONS: This study identified the increasing use of gabapentinoids in IDO, describing the profile and overdose characteristics of presentations. It is important for clinicians to exercise vigilance while prescribing gabapentinoids, including being aware of other medications that their patients may have access to. Our findings support the need for routine monitoring for signs of misuse among those prescribed gabapentinoids.
INTRODUCTION: Intentional drug overdose (IDO) is a significant public health problem. Concerns about the misuse of gabapentinoids, i.e. pregabalin and gabapentin, including their consumption in IDO have grown in recent years. This paper examines the trends in the prevalence of gabapentinoids taken in IDO, the profile of individuals taking them, and associated overdose characteristics. METHODS: Presentations to emergency departments involving IDO, recorded by the National Self-Harm Registry Ireland between 1 January 2007 and 31 December 2015 were examined. Data items included patient demographics, drug names, total tablet quantity consumed and alcohol involvement. RESULTS: Gabapentinoids were involved in 2115 (2.9%) of the 72,391 IDOs recorded. Presentations involving a gabapentinoid increased proportionally from 0.5% in 2007 to 5.5% in 2015. The majority of IDOs involving a gabapentinoid were made by females (59.9%), with over one-third (37.2%) involving alcohol. Compared with IDOs involving other drugs, presentations with a gabapentinoid were made by persons who were older (median 37 vs. 32 years) and involved a significantly greater median quantity of tablets (30 vs. 21, p ≤ 0.001), with over one-quarter (27.4%) of these involving the ingestion of 50 tablets or more. Admission to hospital was significantly more common following IDOs with a gabapentinoid compared with those without (49.4% vs. 41.4%, p ≤ 0.001). CONCLUSIONS: This study identified the increasing use of gabapentinoids in IDO, describing the profile and overdose characteristics of presentations. It is important for clinicians to exercise vigilance while prescribing gabapentinoids, including being aware of other medications that their patients may have access to. Our findings support the need for routine monitoring for signs of misuse among those prescribed gabapentinoids.
Authors: Keith Hawton; Helen Bergen; Jayne Cooper; Pauline Turnbull; Keith Waters; Jennifer Ness; Nav Kapur Journal: J Affect Disord Date: 2015-01-08 Impact factor: 4.839
Authors: Jennifer Ness; Keith Hawton; Helen Bergen; Jayne Cooper; Sarah Steeg; Navneet Kapur; Martin Clarke; Keith Waters Journal: Emerg Med J Date: 2015-01-06 Impact factor: 2.740
Authors: Jayne Cooper; Navneet Kapur; Joel Dunning; Else Guthrie; Louis Appleby; Kevin Mackway-Jones Journal: Ann Emerg Med Date: 2006-10 Impact factor: 5.721
Authors: Keith Hawton; Helen Bergen; Deborah Casey; Sue Simkin; Ben Palmer; Jayne Cooper; Nav Kapur; Judith Horrocks; Allan House; Rachael Lilley; Rachael Noble; David Owens Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2007-05-21 Impact factor: 4.328
Authors: Ivan J Perry; Paul Corcoran; Anthony P Fitzgerald; Helen S Keeley; Udo Reulbach; Ella Arensman Journal: PLoS One Date: 2012-02-20 Impact factor: 3.240
Authors: Eve Griffin; Paul Corcoran; Linda Cassidy; Amanda O'Carroll; Ivan J Perry; Brendan Bonner Journal: BMJ Open Date: 2014-07-29 Impact factor: 2.692
Authors: Kirk E Evoy; Sarvnaz Sadrameli; Jillian Contreras; Jordan R Covvey; Alyssa M Peckham; Megan D Morrison Journal: Drugs Date: 2021-01 Impact factor: 9.546